Department of Respiratory Failure
2023年11月8日掲載
Research Theme
Director, Toru ARAI
- Acute exacerbation of interstitial pneumonias
- Prognostic factors, predictive factors, and new treatment
- Idiopathic pulmonary fibrosis
2-2. Serum biomarkers
2-3. Anti-fibrotic therapy; effects and management of adverse events
- Pleuro-parenchymal fibroelastosis (PPFE)
3-2. Biomarkers of PPFE
- Clinical significance of cryobiopsy specimens
- Pulmonary alveolar proteinosis; PAP
- Physiological aspects of interstitial lung diseases (ILDs) and autoimmune pulmonary alveolar proteinosis (APAP)
5-3. Rehabilitation before and after WLL
5-4. Fibrosing PAP
5-5. COVID-19 with PAP
5-6. APAP complicated with sarcoidosis
5-7. GM-CSF inhalation therapy
- Lymphangioleiomyomatosis
6-2. Sirolimus treatment
Publications
1) Arai T, Inoue Y. Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist. ERJ Open Res. 2022 Sep 26;8(3):00242-2022.
2) Arai T, Hirose M, Kagawa T, Hatsuda K, Inoue Y. Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis. J Thorac Dis. 2022 Feb;14(2):278-294.
3) Arai T, Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, Inoue Y. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Can Respir J. 2022 Mar 29;2022:1107673.
4) Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Fujita Y, Hayashi S, Inoue Y. Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. Can Respir J. 2021 Dec 20;2021:4595019.
5) Arai T, Matsuoka H, Hirose M, Kida H, Yamamoto S, Ogata Y, Mori M, Hatsuda K, Sugimoto C, Tachibana K, Akira M, Inoue Y. Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. BMJ Open Respir Res. 2021 Jul;8(1):e000889.
6) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020 May;7(1):e000558.
7) Arai T, Akira M, Sugimoto C, Tachibana K, Inoue Y, Shintani S, Okuma T, Kasai T, Hayashi S, Inoue Y. Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. J Thorac Dis. 2020 Aug;12(8):4132-4147.
8) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020 May;7(1):e000558.
9) Arai T, Kasai T, Shimizu K, Kawahara K, Katayama K, Sugimoto C, Hirose M, Okamoto H, Tachibana K, Akira M, Inoue Y. Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. Intern Med. 2020 Oct 15;59(20):2539-2546.
10) Arai T, Inoue Y. Is corticosteroid use truly not associated with improved outcomes in AE-IPF? Respirology. 2020 Jun;25(6):659. doi: 10.1111/resp.13826. Epub 2020 Apr 19. PMID: 32307850.
11) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Edahiro R, Hamasaki T, Inoue Y; Osaka Acute Exacerbation of Interstitial Pneumonia Research Group. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2019 Jul;24(7):658-666.
12) Arai T, Inoue Y. Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. Respirology. 2018 May;23(5):546-547.
13) Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, Akira M, Kitaichi M, Hayashi S, Inoue Y. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017 Oct;22(7):1363-1370.
14) Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Kitaichi M, Akira M, Hayashi S, Inoue Y. Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology. 2016 Nov;21(8):1431-1437.
15) Arai T, Inoue Y, Akira M, Nakata K, Kitaichi M. Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. Intern Med. 2015;54(24):3177-80.
16) Arai T, Inoue Y, Sugimoto C, Inoue Y, Nakao K, Takeuchi N, Matsumuro A, Hirose M, Nakata K, Hayashi S. CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. Respirology. 2014 Feb;19(2):246-252.
17) Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014 Mar;52(2):136-43.
18) Arai T, Inoue Y, Tachibana K, Tsuyuguchi K, Nishiyama A, Sugimoto C, Sasaki Y, Kagawa T, Matsuda Y, Hayashi S. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology. 2013 Jan;18(1):117-24.
19) Arai T, Inoue Y, Eishi Y, Yamamoto S, Sakatani M. Propionibacterium acnes in granulomas of a patient with necrotizing sarcoid granuolmatosis. Thorax 2008; 63: 90-91
20) Arai T, Inoue Y, Hayashi S, Akira M, Yamamoto S, Travis WD, Sakatani M. Intractable Desquamative Interstitial Pneumonia in a tattooed man. Intern Medi 2006; 45: 1055-8
21) Arai T, Inoue Y, Hayashi S, Yamamoto S, Sakatani M. Risedronate-induced BOOP complicated with Sarcoidosis. Thorax 2005; 60: 613-614
22) Arai T, Inoue Y, Yamamoto S, Akira M, Uesugi H, Hayashi S, Sakatani M. Incipient stage of pulmonary Langerhans’-cell histiocytosis complicated with pulmonary tuberculosis happened to be examined by high resolution computed tomography. Respir Med 2005; 99: 1188-1190
23) Arai T, Hamano E, Inoue Y, Tazawa R, Nukiwa T, Sakatani M, Nakata K. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Respir Med 2004: 98(12): 1227-30
24) Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol. 2000; 278(5): L914-922
2) Arai T, Hirose M, Kagawa T, Hatsuda K, Inoue Y. Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis. J Thorac Dis. 2022 Feb;14(2):278-294.
3) Arai T, Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, Inoue Y. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Can Respir J. 2022 Mar 29;2022:1107673.
4) Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Fujita Y, Hayashi S, Inoue Y. Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. Can Respir J. 2021 Dec 20;2021:4595019.
5) Arai T, Matsuoka H, Hirose M, Kida H, Yamamoto S, Ogata Y, Mori M, Hatsuda K, Sugimoto C, Tachibana K, Akira M, Inoue Y. Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. BMJ Open Respir Res. 2021 Jul;8(1):e000889.
6) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020 May;7(1):e000558.
7) Arai T, Akira M, Sugimoto C, Tachibana K, Inoue Y, Shintani S, Okuma T, Kasai T, Hayashi S, Inoue Y. Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. J Thorac Dis. 2020 Aug;12(8):4132-4147.
8) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res. 2020 May;7(1):e000558.
9) Arai T, Kasai T, Shimizu K, Kawahara K, Katayama K, Sugimoto C, Hirose M, Okamoto H, Tachibana K, Akira M, Inoue Y. Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. Intern Med. 2020 Oct 15;59(20):2539-2546.
10) Arai T, Inoue Y. Is corticosteroid use truly not associated with improved outcomes in AE-IPF? Respirology. 2020 Jun;25(6):659. doi: 10.1111/resp.13826. Epub 2020 Apr 19. PMID: 32307850.
11) Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Edahiro R, Hamasaki T, Inoue Y; Osaka Acute Exacerbation of Interstitial Pneumonia Research Group. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2019 Jul;24(7):658-666.
12) Arai T, Inoue Y. Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. Respirology. 2018 May;23(5):546-547.
13) Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, Akira M, Kitaichi M, Hayashi S, Inoue Y. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017 Oct;22(7):1363-1370.
14) Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Kitaichi M, Akira M, Hayashi S, Inoue Y. Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology. 2016 Nov;21(8):1431-1437.
15) Arai T, Inoue Y, Akira M, Nakata K, Kitaichi M. Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. Intern Med. 2015;54(24):3177-80.
16) Arai T, Inoue Y, Sugimoto C, Inoue Y, Nakao K, Takeuchi N, Matsumuro A, Hirose M, Nakata K, Hayashi S. CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. Respirology. 2014 Feb;19(2):246-252.
17) Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014 Mar;52(2):136-43.
18) Arai T, Inoue Y, Tachibana K, Tsuyuguchi K, Nishiyama A, Sugimoto C, Sasaki Y, Kagawa T, Matsuda Y, Hayashi S. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology. 2013 Jan;18(1):117-24.
19) Arai T, Inoue Y, Eishi Y, Yamamoto S, Sakatani M. Propionibacterium acnes in granulomas of a patient with necrotizing sarcoid granuolmatosis. Thorax 2008; 63: 90-91
20) Arai T, Inoue Y, Hayashi S, Akira M, Yamamoto S, Travis WD, Sakatani M. Intractable Desquamative Interstitial Pneumonia in a tattooed man. Intern Medi 2006; 45: 1055-8
21) Arai T, Inoue Y, Hayashi S, Yamamoto S, Sakatani M. Risedronate-induced BOOP complicated with Sarcoidosis. Thorax 2005; 60: 613-614
22) Arai T, Inoue Y, Yamamoto S, Akira M, Uesugi H, Hayashi S, Sakatani M. Incipient stage of pulmonary Langerhans’-cell histiocytosis complicated with pulmonary tuberculosis happened to be examined by high resolution computed tomography. Respir Med 2005; 99: 1188-1190
23) Arai T, Hamano E, Inoue Y, Tazawa R, Nukiwa T, Sakatani M, Nakata K. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Respir Med 2004: 98(12): 1227-30
24) Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol. 2000; 278(5): L914-922